tbuckley/cabot-search huggingface dataset:
Abstract P3-14-03: Differences in pathological and biological factors between DCIS, DCIS with microinvasion (DCIS-MI) and DCIS with concomitant invasive ductal carcinoma (DCIS-IDC).
Authors: G MacGrogan, MC Baranzelli, JM Picquenot, F Penault-Llorca, MC Mathieu, P Tas, V Fermeaux, E Mery, C Sagan, C Blanc-Fournier, E Brabencova, L Arnould, J Jacquemier, F Ettore, V Velasco, B Gonzalves, V Brouste, de Lara C Tunon
Journal: Cancer Research (2012)

Abstract Background: Specific pathological and biological factors differentiating pure DCIS, DCIS with microinvasion (DCIS-MI) and DCIS with concomitant invasive ductal carcinoma (DCIS-IDC) are currently unknown. Identification of such factors would enable us to better understand the transition from an in situ to an invasive carcinoma and improve patient management for patients diagnosed with extensive DCIS. Methods: We previously performed a prospective surgical study demonstrating the benefit of performing upfront sentinel lymph node (SLN) biopsy in patients with extensive DCIS or DCIS-MI undergoing mastectomy. In that study, 196 DCIS and 31 DCIS-MI diagnosed on vacuum-assisted macrobiopsies underwent mastectomy and SLN biopsy. Final pathological status after mastectomy examination revealed 117 DCIS, 38 DCIS-MI, 69 DCIS-IDC, and in 3 cases no residual disease was found. The mastectomy specimens of 216 cases (111 DCIS, 37 DCIS-MI, 68 DCIS-IDC) were available for central pathological review and a TMA containing DCIS lesions of 214 cases (110 DCIS, 36 DCIS-MI, 68 DCIS-IDC) was performed. DCIS morphological features (histological size, nuclear grade, comedo necrosis, inflammation) and immunohistochemical factors (ER, PR, Ki-67 and Her2) were assessed in each of the three groups and compared using Chi2 or Wilcoxon tests. Results: Median histological DCIS sizes did not significantly differ between DCIS and DCIS-MI groups (70mm [4–160] and 60mm [4–180], respectively, p = 0.33), nor between DCIS and DCIS-IDC (70mm [4–160] and 65 mm [10–140], respectively, p = 0.98). DCIS nuclear grade was significantly higher in DCIS-MI compared to DCIS (p = 0.01), but there was no difference in nuclear grade between DCIS and DCIS-IDC (p = 0.22). Comedo necrosis was more often present in DCIS-MI compared to DCIS (p = 0.04), and no such difference was found between DCIS and DCIS-IDC (p = 0.81). Stromal inflammation surrounding DCIS was more often found in DCIS-MI and DCIS-IDC compared to DCIS (p = 0.03 and p &amp;lt; 0.001, respectively). DCIS-MI was more often ER-negative than DCIS (p = 0.009), and no such difference was found between DCIS and DCIS-IDC (p = 0.6). No other significant differences concerning PR and Her2 status or Ki-67 index were found between the 3 groups. Conclusions: In patients with extensive DCIS there are few morphological or current immunohistochemical factors differentiating in situ cases from those that have associated microinvasion or invasive ductal carcinoma. DCIS-MI cases have more aggressive histological features than DCIS. Stromal inflammation surrounding DCIS was the only feature distinguishing DCIS from DCIS-IDC. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-14-03.
P1146 VIROLOGICAL RESPONSE AND TOLERANCE TO BOCEPREVIR OR TELAPREVIR PLUS PEGINTERFERON ALFA-2a/RIBAVIRIN TRIPLE THERAPY IN HIV–HCV CO-INFECTED PATIENTS: REAL-LIFE FINDINGS FROM THE PAN STUDY
Authors: A. Baumgarten, S. Holm, T. Lutz, D. Schranz, S. Mauss, H. Hillenbrand, A. Moll, S. Scholten, W. Schmidt, J. Goelz, B. Hintsche, D. Schleehauf, S. Fenske, C. Stephan, D. Prziwara, S. Koeppe, U. Alshuth, H. Jaeger
Journal: Journal of Hepatology (2014)
Abstract 1792: Association of enhanced IGF-1R signaling and HBV/inflammation with poor HCC prognosis
Authors: Te-Sheng Chang, Kam-Fai Lee, Shui-Yi Tung, Liang Mou Kuo, Yen-Hua Huang
Journal: Cancer Research (2010)

Abstract Hepatocellular cell carcinoma (HCC) associated with chronic HBV hepatitis tends to have a more unfavorable prognosis. Recently, a global transcriptome analysis by Boyault's group suggested that HBV infection would result in chromosome instability and activation of insulin-like growth factor receptor (IGFR)/AKT signaling pathway (but not the β-catenin pathway) of a subgroup of HCC. As both chronic inflammation and viral infection have been demonstrated to be important promoters for HCC tumorigenesis, we investigated the potential effects of HBV and chronic inflammation on the activation of IGF signaling pathway. By using the paired HBV- positive and HBV-negative HCC cell lines (HepG2.2.15 (HBV+) vs. HepG2 (HBV-); and Hep3B (HBV+) vs. Huh7 (HBV-)), we found the increased expression of IGF1 receptor at both gene (by RT PCR) and protein levels (by Western blotting) in HBV-positive HCC cell lines. Meanwhile, the IGF-1R activation signaling (such as phospho-IGF-1R and phospho-Akt) was also significantly increased in HBV-positive HCC cell line (Hep3B vs. Huh7). To further examine the role of inflammatory cytokine(s) in IGF-1 signaling of HCC cells, increasing dilution folds of LPS (lipopolysaccharide)- stimulated monocyte-differentiated U937 cell condition medium (U937-CM) were added in culture medium for treatment of HepG2 and HepG2.2.15 cells. By Western blotting analysis, the chronic inflammation condition showed enhancement of the IGF-1R protein expression in the HepG2.2.15 while comparing with the HepG2 cells. These observations suggested that the inflammatory stress may further elevate the IGF-1R expression in HBV-positive HepG.2.2.15 cell line. The associated clinical implication was further evaluated by high throughput tissue microarray. Our results revealed a negative correlation between phospho-IGF-1R expression and disease-free survival. In summary, our work showed that both HBV and chronic inflammation promoted IGF-1R activation signaling which may result in the poor prognosis of a subgroup of HCCs. The underlying mechanism(s) contributing the IGF-1R-mediated signal to the ominous disease outcome still needs further investigation. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1792.
344 PERIPHERAL HCV-SPECIFIC CYTOTOXIC RESPONSE DETECTION AT WEEK 12 OF PEGYLATED-INTERFERON alfa-2b PLUS RIBAVIRIN TREATMENT FOR CHRONIC HCV INFECTION CORRELATES WITH SUSTAINED VIROLOGIC RESPONSE DEVELOPMENT
Authors: J.R. Larrubia, M.U. Lokhande, J. Miquel, S. García-Garzón, A. González-Praetorious, E. Sanz-de-Villalobos
Journal: Journal of Hepatology (2013)
THU0236 Brachial Artery Vasodilator Function and Adhesion Molecules in Rheumatoid Arthritis
Authors: A. Syngle, N. Garg, I. Verma, P. Krishan
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Cardiovascular (CV) event rates are increased in Rheumatoid Arthritis (RA). Traditional cardiovascular risk factors do not adequately account for the extent of cardiovascular disease in RA<sup>1</sup>. The relation among biomarkers of endothelial dysfunction, inflammation and vascular function remain uncertain. Hence, we investigated the relationship between biomarkers of endothelial dysfunction, inflammation and vascular function in RA patients. <h3>Objectives</h3> To investigate the relationship between biomarkers of endothelial dysfunction, inflammation and vascular function in RA patients. <h3>Methods</h3> 30 adult RA patients (4 male, 26 female) and 30 age and sex matched healthy controls (6 male, 24 female) were enrolled in the study. Assessment of FMD done by Angiodefender™ (Everest Genomic, United States). Soluble adhesion molecules (sICAM-1 and sVCAM-1) and pro-inflammatory cytokines (TNF-α, IL-6 and IL-1) was measured using standard ELISA kits. As surrogates for disease activity, DAS28, C-reactive protein and ESR levels were determined. <h3>Results</h3> Compared with healthy controls, RA patients had significantly (p&lt;0.05) increased basal concentrations of soluble intracellular adhesion molecules (sICAM-1), soluble vascular cell adhesion molecule (sVCAM-1), tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 (IL-1). A significant negative correlation was found between VCAM-1 and FMD (P&lt;0.05) and positive correlation was found between VCAM-1 and TNF-α (P&lt;0.05). while sICAM-1 was positively correlated with IL-1 (P&lt;0.05). A significant positive correlation was found between VCAM-1 and inflammatory measures like DAS28 and CRP in RA patients. <h3>Conclusions</h3> In RA, endothelial activation correlates with FMD, through inappropriate secretion of cytokines. Our, study findings support the possibility that systemic inflammation may represent a mechanistic link between adhesion molecules and vascular dysfunction. This suggests that the expression of cell adhesion molecules is up regulated by pro-inflammatory cytokines and association with endothelial dysfunction may have a central role in the mechanism of immune-mediated inflammation and atherosclerosis. This is the first study which shows a relationship between adhesion molecule and vascular function assessed by brachial artery flow mediated vasodilatation. This study opens the possibility of employing therapeutic agents to protect the vessels from the effects of adhesion molecules. <h3>References</h3> Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36-40. <h3>Acknowledgements</h3> This study was supported by Research Grant from Universal Grant Commission, New Delhi [F. No.41-725/2012 (SR)]. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5330
Abstract 39: Specific amino acid restriction affects glucose metabolism and induces oxidative damage of mitochondria in prostate cancer cells
Authors: Ya-Min Fu, Xiaoyi Liu, Gary G. Meadows
Journal: Cancer Research (2010)

Abstract The purpose of this study was to examine how specific amino acid restriction targets mitochondria to induce apoptosis in DU145 and PC3 prostate cancer cells. This study shows that restriction of tyrosine and phenylalanine (Tyr/Phe), glutamine (Gln), and methionine (Met) differentially modulates glucose metabolism, the activity of pyruvate dehydrogenase (PDH) and antioxidant status in the mitochondria of these two cell lines. In DU145 cells, Gln and Met restriction but not Tyr/Phe restriction, increase glucose consumption and decrease lactate production. All the examined restrictions increase mitochondrial PDH activity and reactive oxygen species (ROS). Gln and Met restriction increase mitochondrial activity of glutathione peroxidase (GPx). Tyr/Phe and Met restriction increase mitochondrial activity of manganese superoxide dismutase (SOD) in the first 2 days of the restriction, and the activity returns to basal level on day 4 of restriction. Moreover, all the examined restrictions decrease reduced glutathione (GSH) and cause mitochondrial DNA damage. In PC3 cells, all of the examined restrictions reduce glucose consumption and lactate production; however, they do not alter mitochondrial PDH activity. Gln restriction increases accumulation of ROS and elevates mitochondrial GPx activity. Tyr/Phe restriction increases mitochondrial activity of SOD during the entire restriction period. Although all the restrictions decrease GSH in PC3 cells, they do not cause mitochondrial DNA damage. The data indicate that specific amino acid dependency differentially regulates glucose metabolism, oxidation-reduction reactions of mitochondria, and oxidative damage in mitochondria of these two cell lines. This partially explains how selective amino acid restriction targets mitochondria to induce apoptosis. (The project described was supported by Award Number R01CA101035 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 39.
The Prevalence of Anti-Bovine Serum Albumin Antibodies in Japanese Children With IDDM
Authors: Shigetaka Sugihara, Mizuko Kazukawa, Susumu Konda, Atsushi Murata, Kunio Wataki, Yasuyuki Kobayashi, Shigeki Miyamoto, Nozomu Sasaki, Hiroo Niimi
Journal: Diabetes Care (1996)
AB1082 Management of gout in patients hospitalized with heart failure:
Authors: S.C. Kim, D.H. Solomon
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Both gout and hyperuricemia are associated with an increased risk of cardiovascular disease such as heart failure (HF). Recent data show that a history of gout and an acute episode of gout are risk factors for HF readmission and mortality.<sup>1</sup> <h3>Objectives</h3> Our objective was to describe characteristics of patients with HF and gout and evaluate current practice patterns for acute and maintenance therapy for gout in the setting of HF exacerbation. <h3>Methods</h3> Adult patients who were hospitalized for at least a day with primary diagnosis of HF at an academic medical center (2007-2010) were eligible (n=2,407). Of those, we reviewed the electronic medical records of 161 patients who had a serum uric acid level checked during the index hospitalization; individuals who had either history of gout or acute gouty flare during hospitalization were eligible. Patients with hematologic malignancies undergoing chemotherapy as well as in-hospital deaths were excluded. Data on demographic characteristics, admission and discharge date, comorbid conditions, serum uric acid level, and gout characteristics and treatment were analyzed. <h3>Results</h3> A total of 74 patients, 16 with a new diagnosis of gout and 58 with a history of gout, were identified (see Table). Among the 58 patients with a history of gout, 22 (38%) developed a flare up during hospitalization. 30 (52%) of patients with a history of gout were on allopurinol, daily dosing ranged from 50mg to 600mg (median: 100mg). Nearly all patients (97%) on allopurinol had a serum uric acid level higher than 6.0mg/dl (median: 9.43mg/dl). 34% of patients who had acute gout during hospitalization had a polyarticular attack. Most patients had significant comorbidities such as diabetes (39%), chronic kidney disease (60%) and coronary artery disease (43%). Among the patients with an acute gout flare (n=38), common treatments were colchicine (53%) and/or oral corticosteroids (45%). Less than 10% received intra-articular steroid injections and none took an NSAID. <h3>Conclusions</h3> Our study showed that almost all patients with gout and HF were hyperuricemic, most despite the use of allopurinol. Since the HF population is at high risk of gout attacks, more aggressive dose titration with uric acid lowering therapy may be warranted. <h3>References</h3> Thanassoulis G, Brophy J, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170(15):1358-1364. <h3>Disclosure of Interest</h3> S. Kim Grant/Research support from: Pfizer, Takeda, D. Solomon Grant/Research support from: Pfizer, Amgen, BMS, Abbot
Increased 5-HT&lt;char aid="99820963" id="sub"&gt;2A&lt;/char&gt; Receptor Binding in Euthymic, Medication-Free Patients Recovered From Depression: A Positron Emission Study With [&lt;char aid="99820964" id="sup"&gt;11&lt;/char&gt;C]MDL 100,907
Authors: Zubin Bhagwagar
Journal: American Journal of Psychiatry (2006)

Objective: A previous positron emission tomography (PET) study reported increased serotonin 5-HT 2A receptor binding in unmedicated depressed patients with high scores on the Dysfunctional Attitudes Scale. The purpose of the present study was to use the highly selective 5-HT 2A receptor ligand [ 11 C]MDL 100,907 in a PET imaging paradigm to assess 1) 5-HT 2A receptor binding potential in euthymic subjects with a history of recurrent depression and 2) the relationship between receptor binding and scores on the Dysfunctional Attitudes Scale. Method: Cortical 5-HT 2A receptor binding was measured in 20 unmedicated, fully recovered unipolar depressed patients and 20 age- and gender-matched comparison subjects. Regional estimates of binding potential were obtained using a reversible plasma input function compartmental model and the cerebellum as a reference region to estimate the free and non-specifically bound [ 11 C]MDL 100,907 in brain tissue. Results: Relative to the comparison subjects, the recovered depressed patients demonstrated significantly higher 5-HT 2A receptor binding potential in the frontal cortex (mean increase: 19%), parietal cortex (mean increase: 25%), and occipital cortex (mean increase: 19%). 5-HT 2A receptor binding potential correlated negatively with age in both patients and comparison subjects and positively with the Dysfunctional Attitudes Scale in the recovered patients. Conclusions: These findings should be considered preliminary but suggest that recovered subjects with a history of recurrent major depression have elevated binding potential of cortical 5-HT 2A receptors. The correlation of increased 5-HT 2A receptor binding potential with increased scores on Dysfunctional Attitudes Scale supports earlier work suggesting that increased 5-HT 2A receptor availability characterizes a group of depressed patients with high levels of dysfunctional attitudes.
Abstract ADV12: Banner Good Samaritan Medical Center's Oncology Program.
Authors: Bonita Jones
Journal: Cancer Research (2013)

Abstract Banner Good Samaritan Medical Center in Phoenix, Arizona is the flagship medical center within Banner Health with over 650 beds. Our medical center has been consistently ranked as one of America's "Best Hospitals" by U.S. News &amp; World Report. Banner Good Samaritan Medical Center's mission statement: We exist to make a difference in the lives of the people we serve through excellent patient care. Banner Good Samaritan's cancer program offer's state-of-the-art inpatient and outpatient services, advanced detection and treatments along with a wide range of support services for all types of cancer including breast cancer, lung cancer, head and neck cancers, leukemia and colorectal/pancreas/liver cancers. Citation Format: Bonita Jones. Banner Good Samaritan Medical Center's Oncology Program. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV12. doi:10.1158/1538-7445.AM2013-ADV12
Pyogenic granuloma mimicking a colon cancer
Authors: Yasuhiko Hamada, Kyosuke Tanaka, Syunsuke Tano, Takashi Kitade, Masaki Katsurahara, Noriyuki Horiki, Yoshiyuki Takei
Journal: Endoscopy (2014)

A 59-year-old man with a history of chronic myelogenous leukemia underwent colonoscopy because of altered bowel habit. Conventional colonoscopy showed a reddish, irregular shaped, semipedunculated polyp in the rectum, approximately 10 mm in diameter ([Fig. 1]). Magnifying endoscopy with indigo carmine revealed a smooth surface without mucosal pits ([Fig. 2]). Magnifying endoscopy with narrow band imaging showed many microvessels with a congested network pattern ([Fig. 3]). A colon cancer was considered by colonoscopic findings. However, histopathology of biopsies showed inflammatory granulation tissue and no evidence of cancer. Endoscopic ultrasound revealed that the lesion was confined to the mucosal layer and that the submucosal layer was intact ([Fig. 4]). The lesion was removed by endoscopic mucosal resection for accurate diagnosis. Histopathologically, the lesion consisted mainly of inflammatory granulation tissue and was covered with regenerating epithelium. It was diagnosed as a pyogenic granuloma ([Fig. 5] and [Fig. 6]).
TI-201 vs Tc-99m MIBI SCINTIGRAPHY FOR DETECTION OF RESIDUAL THYROID CANCER
Authors: M. E. Schurrer, J. E. Seabold, R. Aktay, P. T. Kirchner, N. J. Gurll
Journal: Clinical Nuclear Medicine (1998)

Schurrer, M. E.; Seabold, J. E.; Aktay, R.; Kirchner, P. T.; Gurll, N. J. Author Information
Abstract 2267: Long term prognostic impact of CD4 and CD8 lymphopenia and rapid recovery in a cohort of 220 patients with a 10 years follow-up
Authors: Julien Peron, Isabelle Ray-Coquard, Philippe Cassier, Intidhar Labidi-Galy, Olivier Tredan, Thomas Bachelor, Catherine Sebban, Pierre Biron, Guillaume Glapisson, Jean-Yves Blay
Journal: Cancer Research (2011)

Abstract Introduction: Lymphopenia is frequently observed in patients with cancer and correlates with poor outcome in short term. We report here the long term 10 years prognosis value of the peripheral blood lymphocyte subsets and impact of lymphocyte variation during the first months of chemotherapy in a cohort of patients treated in 1999 and 2000 with a minimum 10 years follow-up. Patients and methods: Peripheral blood lymphocyte subsets (CD3, CD4, CD8, CD19, CD56) were quantified on Day 1, after 1 and 3 months of a treatment with chemotherapy using FACS in a prospective study of patients with cancer treated in a single oncology ward. Different tumors subtypes, stages and disease settings were included. Correlation of lymphocyte subset counts and variations with outcome was analyzed. Results: Among the 220 included patients, 83 (38%) were treated for lymphoma, 15 (7%) for myeloma, 58 (26%) for sarcoma, 21 (9%) for breast cancer and 43 (19%) for other cancers. In univariate analysis baseline absolute lymphocyte count (ALC) &amp;lt;700/μL, baseline CD4 count &amp;lt; 450/μL and baseline CD8 &amp;lt; 400/μL were found correlated to overall survival (OS) and progression free survival (PFS). In multivariate analysis, absolute lymphocyte count &amp;lt;700/μL (HR 1.7, [95% CI, 1.1 – 2.4], p=0.008) and CD8 counts &amp;lt;400/μL (HR 1.5, [95% CI, 1.1 – 2.1], p=0.019) were found to be independently correlated to overall survival. Among tumors curable with cytotoxic chemotherapy -lymphoma, germ cell cancer thymoma and localized carcinomas), no patients with ALC &amp;lt;200/μL or baseline CD4 lymphocytes &amp;lt;100/ μL had long term survival. Among patients with rarely curable tumors (metastatic carcinomas and sarcomas), patients with baseline ALC &amp;lt;400/μL or baseline CD4 lymphocytes &amp;lt;200/μL died within 18 months. We then investigated the impact of lymphocyte recovery during the first month and 3 months of chemotherapy. In lymphopenic patients (ALC &amp;lt; 700/μL), recovery was not associated with an improved outcome. Conversely, lymphocyte increase between M0 and M1 was associated with a decreased OS (HR: 1.95 CI95% 1.17-3.26, p=0.009) in patients with ALC≥700/μl, in univariate and multivariate analysis. Conclusion: A low absolute lymphocyte count and CD4 or CD8 lymphocyte count is major prognostic factor for overall survival in patients receiving chemotherapy. Early lymphocyte recovery is not associated with improved outcome in these patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2267. doi:10.1158/1538-7445.AM2011-2267